因信息披露违法违规被立案后，监管对嘉应制药（002198）及相关责任人的处罚落地。此前公司在5月 28日晚曾公告，因公司涉嫌信息披露违法违规，中国证监会决定对公司立案。（详见本报5月29日报道 本报报道后，002198被立案调查了！） 8月3日晚间，嘉应制药公告，8月1日，公司及相关责任人李能（现任董事长）、游永平（现任董事、总 经理）、史俊平（时任财务总监）收到中国证监会广东监管局下发的《行政处罚事先告知书》（以下简 称《行政处罚书》），因2.2亿元关联资金拆借未及时披露，嘉应制药及相关责任人合计领490万元罚 单。 嘉应制药及相关责任人领490万元罚单 《行政处罚书》显示，嘉应制药董事长李能是湖南药聚能医药有限公司（以下简称"药聚能"）的实际控 制人，药聚能构成嘉应制药的关联方。2024年10月至2025年1月期间，因药聚能存在短期资金需求，嘉 应制药的子公司嘉应制药（湖南）有限公司（以下简称"湖南嘉应"）以月初转出、月末转回的方式，向 药聚能提供短期资金拆借，单笔发生额在4万元至5999万元之间。其中，2024年度合计转出1.7亿元； 2025年1月转出5000万元，并均于当月转回，累计涉及金额为2.2 ...

Core Viewpoint - Jia Ying Pharmaceutical has received a notice of administrative penalty from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission due to violations related to information disclosure and the misuse of company funds by its chairman and other executives [1][4]. Group 1: Administrative Penalty Details - The company and its responsible persons, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received the notice on August 1, following an investigation initiated on May 28 for suspected violations [1][4]. - The Guangdong Regulatory Bureau plans to impose a warning and a fine of 1.5 million yuan on Jia Ying Pharmaceutical, along with individual fines of 1.6 million yuan for Li Neng, 1 million yuan for You Yongping, and 800,000 yuan for Shi Junping [6]. Group 2: Misuse of Company Funds - Li Neng, as the actual controller of Hunan Yao Juneng Pharmaceutical Co., Ltd., facilitated non-operational fund transfers from Jia Ying Pharmaceutical to the related company, totaling 21.999 million yuan, which accounted for 28.83% of the company's latest audited net assets [4][5]. - The fund transfers occurred between October 2024 and January 2025, with amounts ranging from 40,000 yuan to 59.99 million yuan, and were not disclosed in accordance with regulatory requirements [4][5]. Group 3: Company Background and Financial Performance - Jia Ying Pharmaceutical, established in 2003 and listed in 2007, specializes in the research, production, and sales of traditional Chinese medicine, with a portfolio of 70 products [9]. - The company has experienced stagnant financial performance, with total revenue of 376.2 million yuan and a net profit of 20.61 million yuan reported for the year ending December 31, 2024 [10].

Core Viewpoint - Jia Ying Pharmaceutical (002198) received an administrative penalty notice due to the chairman's misuse of company funds through an affiliated company [1][5] Group 1: Administrative Penalty - The company and responsible individuals, including Chairman Li Neng, General Manager You Yongping, and former CFO Shi Junping, received a notice from the Guangdong Regulatory Bureau of the China Securities Regulatory Commission (CSRC) on August 1 [1][6] - The CSRC decided to investigate the company for suspected violations of information disclosure laws, leading to the administrative penalty [1][5] Group 2: Fund Misappropriation Details - Li Neng, as the actual controller of Hunan Yao Juneng Pharmaceutical Co., Ltd. (an affiliate), facilitated the transfer of funds from Jia Ying Pharmaceutical to this company, which constituted a non-operational fund transfer [5][6] - From October 2024 to January 2025, Jia Ying Pharmaceutical's subsidiary transferred a total of 21.999 million yuan to the affiliate, representing 28.83% of the company's latest audited net assets [5][6] Group 3: Penalties Imposed - The proposed penalties include a warning and a fine of 1.5 million yuan for Jia Ying Pharmaceutical, a warning and a fine of 1.6 million yuan for Li Neng, a warning and a fine of 1 million yuan for You Yongping, and a warning and a fine of 800,000 yuan for Shi Junping [6][7] Group 4: Background of Li Neng - Li Neng became the chairman of Jia Ying Pharmaceutical in August 2024, just two months before the fund misappropriation occurred [8] - He is also the actual controller of the chain pharmacy Yang Tian He, which has over 4,000 stores nationwide and ranks among the top 20 in China's pharmaceutical retail industry [8] Group 5: Company Overview - Jia Ying Pharmaceutical, established in 2003 and listed in 2007, is a Chinese traditional medicine manufacturer with a portfolio of 70 products [9] - The company has maintained modest financial performance, with total revenues around several hundred million yuan and net profits in the tens of millions [9][10]

Core Viewpoint - Dahua Intelligent Technology Co., Ltd. is facing regulatory scrutiny due to multiple violations of information disclosure regulations, leading to a formal investigation by the China Securities Regulatory Commission (CSRC) [2][6]. Group 1: Regulatory Violations - The Fujian Securities Regulatory Bureau identified four major issues with Dahua Intelligent, including failure to disclose significant contracts and financial assistance, undisclosed related party transactions, premature recognition of subsidiary disposal gains, and incorrect accounting for construction projects [8][9][10][11]. - Dahua Intelligent's subsidiary, Fujian Fumi Technology Co., Ltd., entered into a significant contract worth 794.99 million yuan without proper disclosure [8]. - The company failed to disclose a related party transaction involving a fund transfer of 140 million yuan to repay the former chairman [9]. - Dahua prematurely recognized gains of 61.1163 million yuan from the disposal of subsidiaries, inflating profits inaccurately [10]. - The company misclassified expenses related to construction projects, leading to inflated profits of 28.91 thousand yuan in 2022 and 2.92937 million yuan in 2023 [11]. Group 2: Financial Reporting Errors - Dahua Intelligent announced corrections for accounting errors affecting 12 financial reports from 2021 to 2024, including a reduction of cash and net profit adjustments [12][13]. - The 2021 consolidated balance sheet saw a cash reduction of 360 million yuan and a net profit decrease of 13.42 million yuan due to these corrections [12][13]. Group 3: Financial Performance - Dahua Intelligent has reported a continuous decline in its net profit, with a cumulative loss of 1.743 billion yuan from 2018 to 2024 [14]. - The company expects a net loss of 60 million to 40 million yuan for the first half of 2025, continuing its trend of losses [17]. - The decline in profitability is attributed to increased competition, rising material costs, and strategic decisions to exit non-core business lines [18].

Group 1 - The core point of the article is that Micron Optoelectronics is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to potential compensation claims from affected investors [2] - On July 31, Micron Optoelectronics had a trading volume of 78.05 million yuan, with a net inflow of 6.10 million yuan from major investors [2] - The CSRC issued a notice of investigation to Micron Optoelectronics on July 25, 2025, due to alleged violations of the Securities Law and the Administrative Penalty Law of the People's Republic of China [2] Group 2 - The company held its first meeting of the seventh supervisory board on May 20, 2025, with three supervisors present [3] - The meeting resulted in the election of the chairman of the seventh supervisory board, with unanimous approval [4] - Micron Optoelectronics' business scope includes the sale of optical communication equipment, manufacturing and sales of network devices, and various electronic and mechanical equipment [4]

Core Viewpoint - Huizhou Intelligent (002122.SZ) is under administrative supervision measures from the Zhejiang Securities Regulatory Bureau due to its director Chen Youde being identified as a dishonest executor by the court, leading to his resignation [2][3][6] Group 1: Administrative Measures - The Zhejiang Securities Regulatory Bureau issued a corrective measure against Huizhou Intelligent on July 25, 2023, due to Chen Youde's refusal to fulfill obligations determined by a legal document [3] - The company is required to promptly remove Chen Youde from his director position and improve its operational compliance awareness [3][6] Group 2: Resignation of Chen Youde - Chen Youde submitted his resignation on July 28, 2023, and will not hold any position in the company or its subsidiaries after his resignation [2][3] - His resignation does not reduce the board members below the legal minimum, ensuring the normal operation of the board [3] Group 3: Background of Chen Youde - Chen Youde has been a director of Huizhou Intelligent since February 2020 and also serves as the chairman of Sihuo Ju Li Information Technology Group, holding a 33.34% stake in it [4][5] - Sihuo Ju Li has been a major shareholder of Huizhou Intelligent since 2020, currently holding approximately 12.17% of the company [2][4] Group 4: Previous Regulatory Issues - Earlier in April 2023, Huizhou Intelligent received a warning from the Zhejiang Securities Regulatory Bureau for inflating revenue and failing to disclose significant developments regarding a loan contract with Qiqihar Xinhao Run Cheng Real Estate Development Co., Ltd [6][7] - The company is currently under investigation for suspected violations of information disclosure laws, with the China Securities Regulatory Commission having issued a notice of investigation [6][7]

又一上市公司实控人被取保候审。 7月30日，红相股份（300427.SZ）发布公告称，公司实际控制人杨成因涉嫌违法被厦门市公安局 决定取保候审，期限自2025年7月29日起生效。 公告指出，杨成目前未在该公司担任任何职务，该公司日常经营管理由高管团队负责，此事项不会 对日常生产经营活动产生影响。 7月31日，红相股份开盘大跌近5%。据经济观察报统计，6月份以来，这已经是A股市场第三家实 控人被取保候审的上市公司，另外两家分别为中荣印刷集团股份有限公司（301223.SZ）、甬金科 技集团股份有限公司（603995.SH）。 被取保候审背后 7月31日，经济观察报记者致电红相股份证券事务部，一名人员回应称，此次实控人杨成被取保候 审，系因其此前涉及信息披露违法违规相关事项。目前该公司仍在配合公安机关的调查工作。 7月31日，经济观察报记者致电红相股份证券事务部，一名人 员回应称，此次实控人杨成被取保候审，系因其此前涉及信息 披露违法违规相关事项。目前该公司仍在配合公安机关的调查 工作。 作者： 蔡越坤 封图：图虫创意 上述红相股份证券事务部人员所指信息披露违规事项要追溯至2024年上半年。 2024年4月8日， ...

Core Viewpoint - 中船应急因2022年财报信息披露违法违规行为受到湖北证监局的处罚，股票将被实施其他风险警示，简称变更为"ST应急" [1][2] Financial Discrepancies - 中船应急2022年年报存在收入确认和坏账计提不准确的会计差错，导致营业收入多计3137.24万元，占当期营业收入的1.86% [1] - 营业成本多计1839.09万元，占当期营业成本的1.40% [1] - 利润总额多计714.03万元，占2022年当期披露利润总额绝对值的36.64% [1] Penalties and Warnings - 湖北证监局拟对中船应急处以400万元罚款，并对相关责任人处以合计590万元的罚款 [2] - 公司已完成整改，并计划在12个月后申请撤销风险警示 [2] Performance Overview - 中船应急2022年归母净利润亏损528.11万元，为上市以来首次年度亏损 [3] - 2023年亏损进一步扩大至2.17亿元，同比暴跌3996% [3] - 2024年预计营收同比增长92.51%至11.61亿元，净利润扭亏为盈至864万元，但扣非净利润仍亏损1614万元 [3] Stock Performance - 中船应急股票及可转债自7月31日停牌1天，8月1日复牌，7月累计涨幅超30% [3] - 截至7月30日收盘，股价为12.51元/股，总市值为123.46亿元 [3]

【导读】中船应急8月1日起实施其他风险警示，证券简称变为ST应急 中国基金报记者 闻言 7月30日晚间，中船应急公告称，公司股票将自8月1日开市起被实施其他风险警示，证券简 称变为ST应急，股票交易的日涨跌幅限制仍为20%。 中船应急计划自7月31日开市起停牌，8月1日开市起复牌。截至7月30日收盘，中船应急股价 报12.51元/股，涨幅达4.95%，总市值为123.5亿元。截至7月18日，公司股东人数为7.656 万户。 2022年年报涉嫌存在会计差错 7月30日，中船应急及相关当事人收到湖北证监局下发的《行政处罚事先告知书》。《行政处 罚事先告知书》显示，经查明，中船应急涉嫌信息披露违法违规，包括2022年年报披露的财 报存在收入确认和坏账计提不准确的会计差错。 | 正券代码:300527 | 证券简称:中船应急 | 公告编号:202 | | --- | --- | --- | | 债券代码:123048 | 债券简称:应急转债 | | 一是中船应急对部分产品提前确认收入，导致其2022年营业收入多计3137.24万元，营业成 本多计1839.09万元，利润总额多计1298.15万元。 二是中船应急对部分 ...

Core Viewpoint - Dahua Intelligent has been under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure, following previous regulatory penalties related to financial misconduct and inflated profits [1][3]. Financial Misconduct - The company was previously penalized for failing to disclose significant contracts and related financial assistance, resulting in a total profit inflation exceeding 10 million yuan in the 2022 and 2023 annual reports [1][3]. - Dahua Intelligent's subsidiary, Fujian Fumi Technology Co., Ltd., was involved in undisclosed transactions amounting to 1.4 billion yuan and a 7.95 billion yuan contract for financial assistance, which were not reported [3][4]. - The company has adjusted 12 financial reports, reducing cash holdings by 360 million yuan and net profits for 2021 to 2023 by 6.85 million yuan, 5.92 million yuan, and 6.01 million yuan respectively [4]. Financial Performance - Dahua Intelligent has reported a continuous decline in net profits, with a total loss of approximately 3.49 billion yuan from 2018 to 2024 [6][7]. - The company expects a net loss of 55 million to 75 million yuan for the first half of the current year, primarily due to ongoing losses from Fumi Technology and high fixed asset depreciation [4][9]. - The company has been in a state of financial distress, with a cumulative loss of nearly 3.5 billion yuan over seven years, indicating a significant operational challenge [7][8]. Business Strategy and Acquisitions - Dahua Intelligent has engaged in aggressive acquisitions since 2013, expanding into various sectors including third-party payment and financing leasing [7][8]. - Despite initial growth from acquisitions, the company faced substantial losses, particularly from its investment in Runxing Leasing, which led to significant asset write-downs [8][9]. - The company has attempted to divest non-core financial assets to mitigate losses, including the sale of its subsidiary Beijing Huitong and other financial interests [9].